
Opinion|Videos|May 1, 2025
Optimizing Genomic Testing in Breast Cancer: Strategies for Community Practitioners
Panelists discuss how community practitioners face challenges with genomic testing due to working across multiple hospitals with different medical oncology groups who may have varying preferences for assays, emphasizing the importance of communication, established algorithms, and leveraging partnerships with testing companies.
Advertisement
Practical Implementation and Community Practice Challenges
Main Discussion Topics:
- Challenges faced by community practitioners regarding genomic testing
- Implementation of reflex testing strategies based on pathological criteria
- Billing, reimbursement, and ordering logistics in different practice settings
Key Points for Physicians:
- Community practitioners often work across multiple hospitals with different medical oncology groups who may have different testing preferences.
- Electronic portal-based ordering systems and electronic medical record integration improve workflow efficiency.
- Relationships with testing companies can help address reimbursement and coding issues.
Notable Insights:
- Some institutions implement reflex testing criteria based on T and N staging and patient age to improve efficiency.
- Testing companies can be valuable partners in ensuring appropriate coding and test selection.
Clinical Significance: Successful implementation of genomic testing in community settings requires robust communication systems, clear algorithms, and attention to billing/reimbursement considerations to ensure appropriate test utilization.
Advertisement
Related to this article

The FDA has approved neladalkib for previously treated, ALK-positive, locally adanced or metastatic non-small cell lung cancer.

Roswell Park researchers found CD83 CAR T cells could overcome CD19-targeted therapy resistance in preclinical models of B-cell cancers.

Ryan J. Sullivan, MD, discusses HLA testing, liver-directed therapy, and emerging targeted and T-cell–based therapies for metastatic uveal melanoma.

Pertuzumab-qcay is FDA approved for the 3 HER2-positive breast cancer indications of reference pertuzumab.

The European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.

Cretostimogene improved RFS after tumor resection in PIVOT-006, supporting a planned FDA submission for NMIBC.

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
2
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
3
Dr Cortes on the Rationale Behind the OPTIC Trial in CML
4
Localized Prostate Cancer 2026 UPDATE: PSMA PET, ARPI Strategies, and New Trials Reshape Localized Management
5

